Description: Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Home Page: www.tyra.bio
TYRA Technical Analysis
2656 State Street
Carlsbad,
CA
92008
United States
Phone:
619 728 4760
Officers
| Name | Title |
|---|---|
| Dr. Todd Harris Ph.D. | Pres, CEO, Sec., Treasurer & Director |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer |
| Dr. Hiroomi Tada M.D., Ph.D. | Chief Medical Officer |
| Mr. Daniel Bensen | Co-Founder & COO |
| Lynn Scherm | Fin. Director |
| Ms. Esther van den Boom CPA, CPA | Chief Financial Officer |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer |
| Mr. Ali D. Fawaz J.D. | Gen. Counsel & Sec. |
| Dr. Piyush R. Patel Ph.D. | Chief Devel. Officer |
| Amy Conrad | Investor Contact |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 9.9275 |
| Price-to-Book MRQ: | 1.0401 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-09-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 25 |